We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Should Investors Add EYE Stock to Their Portfolios Now?
Read MoreHide Full Article
Key Takeaways
National Vision's comparable sales rose 2.2% as higher tickets offset weaker traffic.
EYE raised 2026 operating income guidance to $119-$139 million and EPS to 94 cents-$1.09.
Higher costs, rising inventory and vendor concentration could weigh on National Vision's performance.
National Vision Holdings, Inc. (EYE - Free Report) is seeing stronger customer spending and premium-product demand offset softer traffic, supporting its comparable-sales outlook. Steady vision-care needs and demand for value-priced eyewear provide a favorable backdrop for the company. National Vision is advancing its transformation through a better customer mix, premium products and digital improvements. Yet rising expenses and heavy reliance on key vendors could weigh on its performance.
The Zacks Rank #2 (Buy) stock has faced a steep pullback over the past 12 months. Shares of the company have fallen 25.8% compared with the 8.9% decline of the industry and the S&P 500 composite’s 16.5% rise.
The leading optical retailer has a market capitalization of $1.37 billion. The company projects long-term estimated earnings growth of 19.5% compared with the industry’s 10.5%. National Vision surpassed earnings estimates in each of the trailing four quarters, delivering an average surprise of 52.5%.
Here’s a closer look at the key factors.
Upsides for EYE Stock
Higher-Value Customer Mix Supports Growth: National Vision continues to benefit from a shift toward higher-value customers and premium products. In the second quarter of 2026, adjusted comparable store sales increased 2.2% as a 7.1% rise in the average ticket offset a 4.9% decline in traffic. Managed care remained positive on both ticket and traffic, while premium lens and frame attachment continued to improve. The e-commerce replatform reduced adjusted comparable sales by an estimated 150 basis points (bps). Excluding this impact, America’s Best would have delivered slightly more than 4% growth. Management now expects fiscal 2026 adjusted comparable store sales growth of 3% to 5%, supported by continued ticket expansion and initiatives such as premium products and store segmentation.
Image Source: Zacks Investment Research
Favorable Industry Trends: National Vision operates in a U.S. optical retail category supported by recurring eye care needs and broad usage of vision correction. Management continues to position the company as a value destination that pairs eye exams with affordable eyewear, which can resonate as consumers seek value without stepping down on branded options. The company’s expanding assortment of premium frames, lenses and smart eyewear is intended to capture demand for more feature-rich products while maintaining its value proposition across banners.
Strategic Transformation Progress: The company’s modernization plan remains centered on underdeveloped customer cohorts, premium products, a better customer experience and disciplined expansion. In the second quarter of 2026, managed care, progressive and outside-Rx customers continued to support a more profitable mix, while premium lens and frame attachment advanced. The America’s Best website replatform is complete, providing the foundation for a unified commerce platform that can connect exams, prescriptions and purchases. Store segmentation was rolled out at America’s Best at the end of the quarter, with Eyeglass World planned by the fourth quarter. Management raised fiscal 2026 adjusted operating income guidance to $119-$139 million and adjusted EPS guidance to be between 94 cents and $1.09. The higher profitability outlook reinforces the potential for the ongoing customer and product mix shift to support further margin expansion.
What Ails National Vision?
Mounting Expenses: National Vision faces higher costs as it shifts toward more premium products and invests in its transformation initiatives. In the second quarter of 2026, costs applicable to revenues rose 60 bps to 41.8% of net revenues, mainly because higher-value products carry a different cost mix. Inventory was also about 37% above the prior-year level as the company stocked more products for store segmentation and premium categories. Management expects inventory growth to slow, but higher inventory could increase markdown and working-capital risk if customer demand weakens.
High Dependence on Vendors: Vendor concentration remains a structural risk in sourcing and fulfillment. In fiscal 2025, approximately 86% of lens expenditures came from one vendor, and nearly 96% of contact lens expenditures were with three vendors. Any disruption in these relationships could affect pricing, product availability and service levels and could limit flexibility if the company needs to react quickly to demand or cost shifts.
EYE Stock Estimate Trend
The Zacks Consensus Estimate for National Vision’s 2026 earnings per share (EPS) has risen 4.3% to 98 cents in the past 30 days.
The Zacks Consensus Estimate for the company’s 2026 revenues is pegged at $2.06 billion. This suggests a 3.8% rise from the year-ago reported number.
Veracyte has an earnings yield of 4.7% against the industry’s negative 1.4% yield. Shares of the company have risen 29.3% against the industry’s 3.8% decline. VCYT’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 41.8%.
Globus Medical, sporting a Zacks Rank #1, has an earnings yield of 6.7% against the industry’s negative 1.4% yield. Its earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 27.9%. GMED shares have rallied 30.1% against the industry’s 3.8% drop over the past year.
Teleflex, carrying a Zacks Rank #2 (Buy), has an estimated long-term earnings growth rate of 20.7% compared with the industry’s 14.5% growth. Its earnings beat estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 3.2%. TFX shares have gained 3.5% against the industry’s 3.7% decline over the past year.
View the Zacks #1 Rank List
Image: Bigstock
Should Investors Add EYE Stock to Their Portfolios Now?
Key Takeaways
National Vision Holdings, Inc. (EYE - Free Report) is seeing stronger customer spending and premium-product demand offset softer traffic, supporting its comparable-sales outlook. Steady vision-care needs and demand for value-priced eyewear provide a favorable backdrop for the company. National Vision is advancing its transformation through a better customer mix, premium products and digital improvements. Yet rising expenses and heavy reliance on key vendors could weigh on its performance.
The Zacks Rank #2 (Buy) stock has faced a steep pullback over the past 12 months. Shares of the company have fallen 25.8% compared with the 8.9% decline of the industry and the S&P 500 composite’s 16.5% rise.
The leading optical retailer has a market capitalization of $1.37 billion. The company projects long-term estimated earnings growth of 19.5% compared with the industry’s 10.5%. National Vision surpassed earnings estimates in each of the trailing four quarters, delivering an average surprise of 52.5%.
Here’s a closer look at the key factors.
Upsides for EYE Stock
Higher-Value Customer Mix Supports Growth: National Vision continues to benefit from a shift toward higher-value customers and premium products. In the second quarter of 2026, adjusted comparable store sales increased 2.2% as a 7.1% rise in the average ticket offset a 4.9% decline in traffic. Managed care remained positive on both ticket and traffic, while premium lens and frame attachment continued to improve. The e-commerce replatform reduced adjusted comparable sales by an estimated 150 basis points (bps). Excluding this impact, America’s Best would have delivered slightly more than 4% growth. Management now expects fiscal 2026 adjusted comparable store sales growth of 3% to 5%, supported by continued ticket expansion and initiatives such as premium products and store segmentation.
Image Source: Zacks Investment Research
Favorable Industry Trends: National Vision operates in a U.S. optical retail category supported by recurring eye care needs and broad usage of vision correction. Management continues to position the company as a value destination that pairs eye exams with affordable eyewear, which can resonate as consumers seek value without stepping down on branded options. The company’s expanding assortment of premium frames, lenses and smart eyewear is intended to capture demand for more feature-rich products while maintaining its value proposition across banners.
Strategic Transformation Progress: The company’s modernization plan remains centered on underdeveloped customer cohorts, premium products, a better customer experience and disciplined expansion. In the second quarter of 2026, managed care, progressive and outside-Rx customers continued to support a more profitable mix, while premium lens and frame attachment advanced. The America’s Best website replatform is complete, providing the foundation for a unified commerce platform that can connect exams, prescriptions and purchases. Store segmentation was rolled out at America’s Best at the end of the quarter, with Eyeglass World planned by the fourth quarter. Management raised fiscal 2026 adjusted operating income guidance to $119-$139 million and adjusted EPS guidance to be between 94 cents and $1.09. The higher profitability outlook reinforces the potential for the ongoing customer and product mix shift to support further margin expansion.
What Ails National Vision?
Mounting Expenses: National Vision faces higher costs as it shifts toward more premium products and invests in its transformation initiatives. In the second quarter of 2026, costs applicable to revenues rose 60 bps to 41.8% of net revenues, mainly because higher-value products carry a different cost mix. Inventory was also about 37% above the prior-year level as the company stocked more products for store segmentation and premium categories. Management expects inventory growth to slow, but higher inventory could increase markdown and working-capital risk if customer demand weakens.
High Dependence on Vendors: Vendor concentration remains a structural risk in sourcing and fulfillment. In fiscal 2025, approximately 86% of lens expenditures came from one vendor, and nearly 96% of contact lens expenditures were with three vendors. Any disruption in these relationships could affect pricing, product availability and service levels and could limit flexibility if the company needs to react quickly to demand or cost shifts.
EYE Stock Estimate Trend
The Zacks Consensus Estimate for National Vision’s 2026 earnings per share (EPS) has risen 4.3% to 98 cents in the past 30 days.
The Zacks Consensus Estimate for the company’s 2026 revenues is pegged at $2.06 billion. This suggests a 3.8% rise from the year-ago reported number.
Other Key Picks
Some other top-ranked stocks in the broader medical space are Veracyte (VCYT - Free Report) , Globus Medical (GMED - Free Report) and Teleflex (TFX - Free Report) .
Veracyte has an earnings yield of 4.7% against the industry’s negative 1.4% yield. Shares of the company have risen 29.3% against the industry’s 3.8% decline. VCYT’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 41.8%.
VCYT sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Globus Medical, sporting a Zacks Rank #1, has an earnings yield of 6.7% against the industry’s negative 1.4% yield. Its earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 27.9%. GMED shares have rallied 30.1% against the industry’s 3.8% drop over the past year.
Teleflex, carrying a Zacks Rank #2 (Buy), has an estimated long-term earnings growth rate of 20.7% compared with the industry’s 14.5% growth. Its earnings beat estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 3.2%. TFX shares have gained 3.5% against the industry’s 3.7% decline over the past year.